Flow cytometric analysis as an additional predictive tool of treatment response in children with chronic-phase chronic myeloid leukemia treated with imatinib

Haruko Shima, Nobutaka Kiyokawa, Masashi Miharu, Akihiko Tanizawa, Hidemitsu Kurosawa, Akihiro Watanabe, Masaki Ito, Chikako Tono, Yuki Yuza, Hideki Muramatsu, Noriko Hotta, Masahiko Okada, Kazuko Hamamoto, Ryosuke Kajiwara, Akiko M. Saito, Keizo Horibe, Shuki Mizutani, Souichi Adachi, Eiichi Ishii, Hiroyuki Shimada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bone marrow samples of newly diagnosed children with chronic-phase chronic myeloid leukemia (CML) were obtained at diagnosis and after imatinib initiation and stained with anti-human CD34, CD38, CD123, CD45RA, cMpl, and lineage antibodies. Flow cytometric analysis revealed that granulocyte macrophage progenitor predominance in CML progenitors at diagnosis and elevated cMpl expression in bone marrow progenitors at 3 months may predict poor outcome in children with chronic-phase CML treated with imatinib. We recommend flow cytometric analysis of bone marrow in the early phase of treatment, as it is a convenient tool that may predict treatment response and guide CML management.

Original languageEnglish
JournalPediatric Blood and Cancer
DOIs
Publication statusAccepted/In press - 2017

    Fingerprint

Keywords

  • Chronic myeloid leukemia
  • CMpl
  • Flow cytometry

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Shima, H., Kiyokawa, N., Miharu, M., Tanizawa, A., Kurosawa, H., Watanabe, A., Ito, M., Tono, C., Yuza, Y., Muramatsu, H., Hotta, N., Okada, M., Hamamoto, K., Kajiwara, R., Saito, A. M., Horibe, K., Mizutani, S., Adachi, S., Ishii, E., & Shimada, H. (Accepted/In press). Flow cytometric analysis as an additional predictive tool of treatment response in children with chronic-phase chronic myeloid leukemia treated with imatinib. Pediatric Blood and Cancer. https://doi.org/10.1002/pbc.26478